Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.930
+0.010 (0.52%)
May 13, 2025, 4:00 PM - Market closed
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
53.63M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GANX News
- 1 day ago - Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 12 days ago - Gain Therapeutics to Participate at The Citizens Life Sciences Conference - GlobeNewsWire
- 13 days ago - Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Announces Poster Presentation at AD/PD 2025 - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - GlobeNewsWire
- 3 months ago - Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - GlobeNewsWire